Cardiology Division of Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
Institute of Clinical Medicine and Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan; Healthcare and Services Center, Taipei Veterans General Hospital, Taipei, Taiwan.
Clin Chim Acta. 2022 Oct 1;535:68-74. doi: 10.1016/j.cca.2022.08.003. Epub 2022 Aug 10.
We investigated the prognostic value of tenascin-C in patients with stable coronary heart disease.
A total of 666 patients were enrolled and followed for 72 months. The primary outcome was a composite of cardiac events. The secondary outcomes were all-cause death, cardiovascular death, acute myocardial infarction (AMI), and heart failure hospitalization.
The area under the curve of tenascin-C to discriminate the occurrence of composite cardiac events was 70 % (95 % CI: 64.2 % to 75.8 %), and the corresponding optimal cutoff value was 19.91 ng/ml. A higher concentration of tenascin-C was associated with a greater risk of composite cardiac events (P trend < 0.001). Similar results were observed in all-cause death, AMI, and heart failure hospitalization.
Tenascin-C was found to be an independent predictor of total cardiovascular events in patients with stable coronary heart disease at 72 months, and also for all-cause death, AMI, and heart failure hospitalization.
我们研究了 tenascin-C 在稳定性冠心病患者中的预后价值。
共纳入 666 例患者，并随访 72 个月。主要终点为心脏事件的复合终点。次要终点为全因死亡、心血管死亡、急性心肌梗死（AMI）和心力衰竭住院。
tenascin-C 预测复合心脏事件发生的曲线下面积为 70%（95%CI：64.2%至 75.8%），最佳截断值为 19.91ng/ml。tenascin-C 浓度越高，发生复合心脏事件的风险越大（P 趋势<0.001）。全因死亡、AMI 和心力衰竭住院也观察到类似的结果。
在 72 个月时，tenascin-C 被发现是稳定性冠心病患者总心血管事件的独立预测因子，也是全因死亡、AMI 和心力衰竭住院的独立预测因子。
